{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:37:00Z","timestamp":1792575420159,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["933283"],"award-info":[{"award-number":["933283"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","award":["P30CA015704"],"award-info":[{"award-number":["P30CA015704"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002576","name":"American Cyronics Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jtct.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:19:53Z","timestamp":1747718393000},"page":"551-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2832-2071","authenticated-orcid":false,"given":"Katelyn","family":"Burleigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-9688","authenticated-orcid":false,"given":"Kelly G.","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-9917","authenticated-orcid":false,"given":"Camille","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Annesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1769-7388","authenticated-orcid":false,"given":"Corinne","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-2397","authenticated-orcid":false,"given":"Bobbie-Jo","family":"Webb-Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-3882","authenticated-orcid":false,"given":"Alexandre V.","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-5821","authenticated-orcid":false,"given":"Heather H.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.05.003_bib0001","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","article-title":"Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"30","author":"Elsallab","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jtct.2025.05.003_bib0002","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer Immunol Immun"},{"key":"10.1016\/j.jtct.2025.05.003_bib0003","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.05.003_bib0004","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.003_bib0005","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.05.003_bib0006","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2025.05.003_bib0007","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0008","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2025.05.003_bib0009","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1182\/bloodadvances.2022008977","article-title":"A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia","volume":"7","author":"Masih","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.003_bib0010","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","article-title":"CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations","volume":"8","author":"Perna","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.003_bib0011","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.05.003_bib0012","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2021-148013","article-title":"Poor clinical outcome in pediatric immunotherapy is mediated by a pre-existing overactive IL-18-IFNy immune phenotype","volume":"138","author":"Burleigh","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0013","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.003_bib0014","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.2023020715","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in Sweden: incidence, clinical characteristics, and survival","volume":"143","author":"L\u00f6fstedt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0015","first-page":"394","article-title":"High pre-transplant Interleukin-18 is associated with poor hematopoietic recovery after allogeneic stem cell transplantation and predicts increased non-relapse mortality","volume":"55","author":"Kordelas","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jtct.2025.05.003_bib0016","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2014-01-549527","article-title":"IFN-\u03b3 causes aplastic anemia by altering hematopoietic stem\/progenitor cell composition and disrupting lineage differentiation","volume":"124","author":"Lin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0017","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","article-title":"Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-\u03b3","volume":"133","author":"Alvarado","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0018","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jtct.2025.05.003_bib0019","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0020","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1158\/2326-6066.CIR-21-0501","article-title":"Modified manufacturing process modulates CD19CAR T-cell engraftment fitness and leukemia-free survival in pediatric and young adult subjects","volume":"10","author":"Ceppi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2025.05.003_bib0021","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4: CD8 composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2025.05.003_bib0022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2008.10.002","article-title":"Validation and comparison of two multiplex technologies, Luminex\u00ae and mesoscale discovery, for human cytokine profiling","volume":"340","author":"Chowdhury","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jtct.2025.05.003_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2011.06.033","article-title":"Multiplex measurement of proinflammatory cytokines in human serum: comparison of the meso scale discovery electrochemiluminescence assay and the cytometric bead array","volume":"372","author":"Dabitao","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jtct.2025.05.003_bib0024","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"INTERFEROME v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtct.2025.05.003_bib0025","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.4049\/jimmunol.167.12.7038","article-title":"Expression and release of IL-18 binding protein in response to IFN-\u03b3","volume":"167","author":"Paulukat","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2025.05.003_bib0026","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.4049\/jimmunol.0902023","article-title":"Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression","volume":"184","author":"Ren","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2025.05.003_bib0027","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cei.13543","article-title":"The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis\/macrophage activation syndrome\u2014a systematic review","volume":"203","author":"Krei","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtct.2025.05.003_bib0028","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.2019003846","article-title":"Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation","volume":"136","author":"Tsoukas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0029","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.jtct.2025.05.003_bib0030","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2025.05.003_bib0031","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2025.05.003_bib0032","doi-asserted-by":"crossref","first-page":"73.e71","DOI":"10.1016\/j.jtct.2021.11.019","article-title":"Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.05.003_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for Cox\u2019s proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jtct.2025.05.003_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jtct.2025.05.003_bib0035","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0036","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2025.05.003_bib0037","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.003_bib0038","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-gamma blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.003_bib0039","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.05.003_bib0040","doi-asserted-by":"crossref","first-page":"73.e71","DOI":"10.1016\/j.jtct.2021.11.019","article-title":"Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.05.003_bib0041","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.003_bib0042","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004567","article-title":"Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy","volume":"10","author":"Johnson","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2025.05.003_bib0044","doi-asserted-by":"crossref","first-page":"72.e71","DOI":"10.1016\/j.jtct.2021.11.014","article-title":"Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.05.003_bib0045","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.05.003_bib0046","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers13153886","article-title":"Why do children with acute lymphoblastic leukemia fare better than adults?","volume":"13","author":"Neaga","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2025.05.003_bib0047","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of ALL in children vs adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematology: Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2025.05.003_bib0048","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/1097-0142(197603)37:3<1256::AID-CNCR2820370305>3.0.CO;2-R","article-title":"Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens","volume":"37","author":"Gee","year":"1976","journal-title":"Cancer"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725011650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725011650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T11:15:11Z","timestamp":1775387711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725011650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666636725011650"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}